drugset / Trial / NCT00262028

Study of the Safety and Immune Response of a Meningococcal Vaccine Administered to Healthy Children

NCT00262028

Phase 2 Completed 910 enrolled Novartis Vaccines
RandomizedParallel-groupSingle-blindPrevention

Summary

The purpose of this study is to evaluate the safety and immunogenicity of Novartis (formerly Chiron) Meningococcal ACWY Conjugate Vaccine administered to healthy children ages 1 - 10 years

Timeline

Start
2005-04
Primary completion
2006-11
Completion
2006-11

Drugs

EvaluationDrugModalityDoseRoute
Subject MenACWY-CRM Vaccine Vaccine
Comparator MenACWY-PS Vaccine Vaccine

Indications